Literature DB >> 8490179

Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.

P Corradini1, M Ladetto, C Voena, A Palumbo, G Inghirami, D M Knowles, M Boccadoro, A Pileri.   

Abstract

The frequency of N- and K-ras oncogene mutations was investigated in plasma cell dyscrasias. Genomic DNAs from 128 patients were selected for this study: 30 monoclonal gammopathies of undetermined significance, 8 solitary plasmacytomas, 77 multiple myelomas (MM), and 13 plasma cell leukemias (PCL). A two-step experimental approach was devised. All samples were screened for mutations by single-strand conformation polymorphism analysis. DNA fragments displaying an altered electrophoretic mobility were further studied by direct sequencing to confirm and characterize the nature of the mutations. Ras mutations are not randomly distributed because they are detectable only in MM (9%) and PCL (30.7%). N-ras codons 12, 13, and 61 and K-ras codon 12 were found to be mutated, but N-ras codon 61 mutation was the most frequent finding (63.6%). In conclusion, ras mutations were found in PCL, and in a subset of MM characterized by advanced-stage disease and adverse prognostic parameters. Furthermore, based on our findings, it is possible to speculate that ras mutations represent a late molecular lesion in the process of multistep carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490179

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Authors:  Kihyun Kim; Sun-Young Kong; Mariateresa Fulciniti; Xianfeng Li; Weihua Song; Sabikun Nahar; Peter Burger; Mathew J Rumizen; Klaus Podar; Dharminder Chauhan; Teru Hideshima; Nikhil C Munshi; Paul Richardson; Ann Clark; Janet Ogden; Andreas Goutopoulos; Luca Rastelli; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Br J Haematol       Date:  2010-03-12       Impact factor: 6.998

3.  Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Naoya Ochiai; Noriko Yamada; Ryo Uchida; Shin-ichi Fuchida; Akira Okano; Mayumi Hatsuse; Masashi Okamoto; Eishi Ashihara; Chihiro Shimazaki
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 4.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 5.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

6.  Primary plasma cell leukemia and autologous stem cell transplantation.

Authors:  Mary B Drake; Simona Iacobelli; Anja van Biezen; Curly Morris; Jane F Apperley; Dietger Niederwieser; Bo Björkstrand; Gösta Gahrton
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

7.  Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.

Authors:  Huixing Zhou; Yuan Jian; Yun Leng; Nian Liu; Ying Tian; Guorong Wang; Wen Gao; Guangzhong Yang; Wenming Chen
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

Review 8.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

9.  Retrotransposition and mutation events yield Rap1 GTPases with differential signalling capacity.

Authors:  Tomasz Zemojtel; Marlena Duchniewicz; Zhongchun Zhang; Taisa Paluch; Hannes Luz; Tobias Penzkofer; Jürgen S Scheele; Fried J T Zwartkruis
Journal:  BMC Evol Biol       Date:  2010-02-19       Impact factor: 3.260

10.  Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.

Authors:  Fazal Shirazi; Richard J Jones; Ram K Singh; Jianxuan Zou; Isere Kuiatse; Zuzana Berkova; Hua Wang; Hans C Lee; Samuel Hong; Larry Dick; Nibedita Chattopadhyay; Robert Z Orlowski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.